While Agios Pharmaceuticals Inc. awaits this summer’s PDUFA date for the IDH-mutant glioma drug vorasidenib, the firm unveiled positive data from a global phase III study...
Edwards Lifesciences Corp. is selling its critical care product group to Becton Dickison and Co. (BD) for $4.2 billion in cash, forgoing its previously announced plans to...
Fibrodysplasia ossificans progressiva is a rare and life-threatening genetic disease caused by gain-of-function mutations in the ALK2 gene, which encodes activin...
China’s Medilink Therapeutics (Suzhou) Co. Ltd. and Germany’s Biontech SE signed another potential $1 billion-plus deal for novel antibody-drug conjugate (ADC) targets,...